Full Press Release Details
BridgeBio Pharma's Origin Biosciences Enters Partnership With Medison To Commercialize BBP-870 In Israel For MoCD Type A.
BBIO
BridgeBio Pharma's Origin Biosciences Enters Partnership With Medison To Commercialize BBP-870 In Israel For MoCD Type A
Key Takeaway: BridgeBio Pharma's Origin Biosciences Enters Partnership With Medison To Commercialize BBP-870 In Israel For MoCD Type A